Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days for obtaining a report for the ctDNA for EGFR Test is 10 days.

What are the prerequisites for the test ctDNA for EGFR Test

  1. Patients must have a confirmed diagnosis of non-small cell lung cancer (NSCLC).
  2. Patients must have a tumor that is positive for EGFR mutations.
  3. Patients must have sufficient blood samples available for testing.
  4. Patients must not have received any EGFR-targeted therapy within a certain timeframe (usually 1-2 weeks) prior to the test.

What are the measure values for the test ctDNA for EGFR Test

  • Positive: EGFR mutation detected
  • Negative: No EGFR mutation detected
  • Indeterminate: Inconclusive result

What does this test ctDNA for EGFR Test identify?

  • EGFR Test identifies mutations in the EGFR gene, specifically in circulating tumor DNA (ctDNA).
  • It is used to detect genetic alterations in EGFR that may be present in certain types of cancer, such as non-small cell lung cancer.
  • Identifying these mutations can help determine the most effective treatment options for patients with EGFR-positive cancer.

Why is this test ctDNA for EGFR Test taken?

Reasons for taking the ctDNA for EGFR Test

The ctDNA for EGFR Test is taken for the following reasons:

  • To identify mutations in the EGFR gene in cancer patients.
  • To determine the presence of EGFR mutations in patients with non-small cell lung cancer (NSCLC).
  • To guide treatment decisions, as certain EGFR mutations are associated with better response to targeted therapies.
  • To monitor disease progression and response to treatment in patients with EGFR mutations.
  • To identify resistance mutations that may develop during treatment with EGFR inhibitors.

No FAQs available.

Customer Google Rating